Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products (drug safety update, 23 November 2023)

Summary

Falsified, potentially harmful Ozempic and Saxenda products have been found in the UK.

This drug safety update from the Medicines and Healthcare products Regulatory Agency (MHRA) asks healthcare professionals to remind patients using these products to always obtain prescription medicines from a qualified healthcare provider and not to use products they suspect are falsified as this may lead to serious health consequences. Healthcare professionals must also remain vigilant for symptoms linked to hypoglycaemia in patients who may have obtained a falsified product containing insulin.

Read the full update and advice for healthcare professionals and the public via the link below.